213 related articles for article (PubMed ID: 22919678)
21. Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits.
Weiss S; Altboum Z; Glinert I; Schlomovitz J; Sittner A; Bar-David E; Kobiler D; Levy H
Antimicrob Agents Chemother; 2015 Dec; 59(12):7497-503. PubMed ID: 26392505
[TBL] [Abstract][Full Text] [Related]
22. In vitro correlate of immunity in a rabbit model of inhalational anthrax.
Pitt ML; Little SF; Ivins BE; Fellows P; Barth J; Hewetson J; Gibbs P; Dertzbaugh M; Friedlander AM
Vaccine; 2001 Sep; 19(32):4768-73. PubMed ID: 11535328
[TBL] [Abstract][Full Text] [Related]
23. Bacillus cereus G9241 makes anthrax toxin and capsule like highly virulent B. anthracis Ames but behaves like attenuated toxigenic nonencapsulated B. anthracis Sterne in rabbits and mice.
Wilson MK; Vergis JM; Alem F; Palmer JR; Keane-Myers AM; Brahmbhatt TN; Ventura CL; O'Brien AD
Infect Immun; 2011 Aug; 79(8):3012-9. PubMed ID: 21576337
[TBL] [Abstract][Full Text] [Related]
24. Structural Integrity of the Alveolar-Capillary Barrier in Cynomolgus Monkeys Challenged with Fully Virulent and Toxin-Deficient Strains of Bacillus anthracis.
D'Agnillo F; Zhang X; Williams MC
Am J Pathol; 2020 Oct; 190(10):2095-2110. PubMed ID: 32598882
[TBL] [Abstract][Full Text] [Related]
25. Expression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbit model of inhalational anthrax.
Lovchik JA; Drysdale M; Koehler TM; Hutt JA; Lyons CR
Infect Immun; 2012 Jul; 80(7):2414-25. PubMed ID: 22526673
[TBL] [Abstract][Full Text] [Related]
26. Dose-Response Modeling for Inhalational Anthrax in Rabbits Following Single or Multiple Exposures.
Gutting BW; Rukhin A; Marchette D; Mackie RS; Thran B
Risk Anal; 2016 Nov; 36(11):2031-2038. PubMed ID: 26889937
[TBL] [Abstract][Full Text] [Related]
27. Transient lipopolysaccharide-induced resistance to aerosolized Bacillus anthracis in New Zealand white rabbits.
Yee SB; Dyer DN; Twenhafel NA; Pitt ML
Comp Med; 2013 Jun; 63(3):252-61. PubMed ID: 23759528
[TBL] [Abstract][Full Text] [Related]
28. Influence of particle size on the pathology and efficacy of vaccination in a murine model of inhalational anthrax.
Thomas R; Davies C; Nunez A; Hibbs S; Flick-Smith H; Eastaugh L; Smither S; Gates A; Oyston P; Atkins T; Eley S
J Med Microbiol; 2010 Dec; 59(Pt 12):1415-1427. PubMed ID: 20798216
[TBL] [Abstract][Full Text] [Related]
29. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge.
Mohamed N; Clagett M; Li J; Jones S; Pincus S; D'Alia G; Nardone L; Babin M; Spitalny G; Casey L
Infect Immun; 2005 Feb; 73(2):795-802. PubMed ID: 15664918
[TBL] [Abstract][Full Text] [Related]
30. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis).
Vasconcelos D; Barnewall R; Babin M; Hunt R; Estep J; Nielsen C; Carnes R; Carney J
Lab Invest; 2003 Aug; 83(8):1201-9. PubMed ID: 12920249
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax.
Gauthier YP; Tournier JN; Paucod JC; Corre JP; Mock M; Goossens PL; Vidal DR
Infect Immun; 2009 Mar; 77(3):1197-207. PubMed ID: 19114543
[TBL] [Abstract][Full Text] [Related]
32. The physiologic responses of Dutch belted rabbits infected with inhalational anthrax.
Lawrence WS; Hardcastle JM; Brining DL; Weaver LE; Ponce C; Whorton EB; Peterson JW
Comp Med; 2009 Jun; 59(3):257-65. PubMed ID: 19619416
[TBL] [Abstract][Full Text] [Related]
33. Key aspects of the molecular and cellular basis of inhalational anthrax.
Cote CK; Welkos SL; Bozue J
Microbes Infect; 2011 Dec; 13(14-15):1146-55. PubMed ID: 21816231
[TBL] [Abstract][Full Text] [Related]
34. Achieving consistent multiple daily low-dose Bacillus anthracis spore inhalation exposures in the rabbit model.
Barnewall RE; Comer JE; Miller BD; Gutting BW; Wolfe DN; Director-Myska AE; Nichols TL; Taft SC
Front Cell Infect Microbiol; 2012; 2():71. PubMed ID: 22919662
[TBL] [Abstract][Full Text] [Related]
35. Cross-species prediction of human survival probabilities for accelerated anthrax vaccine absorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing.
Stark GV; Sivko GS; VanRaden M; Schiffer J; Taylor KL; Hewitt JA; Quinn CP; Nuzum EO
Vaccine; 2016 Dec; 34(51):6512-6517. PubMed ID: 27558619
[TBL] [Abstract][Full Text] [Related]
36. Dissemination bottleneck in a murine model of inhalational anthrax.
Plaut RD; Kelly VK; Lee GM; Stibitz S; Merkel TJ
Infect Immun; 2012 Sep; 80(9):3189-93. PubMed ID: 22753373
[TBL] [Abstract][Full Text] [Related]
37. A synthetic peptide vaccine directed against the 2ß2-2ß3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax.
Oscherwitz J; Yu F; Cease KB
J Immunol; 2010 Sep; 185(6):3661-8. PubMed ID: 20696862
[TBL] [Abstract][Full Text] [Related]
38. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.
Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913
[TBL] [Abstract][Full Text] [Related]
39. Epitope-focused peptide immunogens in human use adjuvants protect rabbits from experimental inhalation anthrax.
Oscherwitz J; Feldman D; Yu F; Cease KB
Vaccine; 2015 Jan; 33(3):430-6. PubMed ID: 25454087
[TBL] [Abstract][Full Text] [Related]
40. Pathology of inhalational anthrax infection in the african green monkey.
Twenhafel NA; Leffel E; Pitt ML
Vet Pathol; 2007 Sep; 44(5):716-21. PubMed ID: 17846250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
